A Phase III Study of Accelerated Whole Breast Radiation Therapy with a Boost versus Standard Whole Breast Radiation with a Boost in Women with Early-Stage Breast Cancer (RTOG 1005)

Full Title
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer (RTOG 1005)

Standard radiation therapy for breast cancer after lumpectomy usually lasts about five weeks. Giving an additional higher dose of radiation to the lumpectomy area further reduces the risk of recurrence but extends the treatment time to six or six and a half weeks.

Accelerated radiation therapy with “hypofractionation” involves giving a higher dose of radiation on fewer days over only three weeks. Studies have shown that the risk of breast cancer recurrence is comparable between this approach and the standard five-week radiation schedule. However, it is not known if a radiation boost can be given at the same time as the accelerated radiation treatments.

The purpose of this Radiation Therapy Oncology Group study is to compare accelerated radiation with a daily radiation boost to standard radiation therapy with a boost added on after the five-week regimen is completed. Patients will be randomly assigned to one treatment schedule or the other. It is expected that the two treatments will be at least comparable in their effectiveness for reducing breast cancer recurrence, but the accelerated radiation schedule may be more convenient and save time and costs.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be women with early-stage breast cancer that has been removed via lumpectomy.
  • Patients must be candidates for radiation therapy.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Preeti Parhar at 908-542-3100.

Breast Cancer
Related Diseases